This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patwari, P. Articles by Lee, R. T. Search for Related Content PubMed Articles by Patwari, P. Articles by Lee, R. T.

(American Journal of Pathology. 2007;170:805-808.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.061243

Commentary

Thioredoxins, Mitochondria, and Hypertension

From Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Abstract

Endothelial dysfunction, often demonstrated by the loss of the endothelial cell’s ability to cause vasodilation in response to appropriate stimuli, is one of the earliest events in the development of atherosclerosis. This has led to intense investigation of the factors affecting both the production and the degradation of NO, the endothelium-derived relaxing factor and a primary mediator of endothelial function. Reactive oxygen species (ROS), particularly superoxide anion, are well known to inhibit NO, and therefore the mechanisms by which endothelium regulates production of ROS are also of high interest. In this issue of The American Journal of Pathology, Zhang et al¹ demonstrate regulation of such events by a mitochondria-specific thioredoxin, which reduces oxidative stress and increases NO bioavailability, thus preserving vascular endothelial cell function and preventing atherosclerosis development.

This article has been cited by other articles:

				T. Ebrahimian, M. R. Sairam, E. L. Schiffrin, and R. M. Touyz Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1481 - H1488. [Abstract] [Full Text] [PDF]